Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases

Modern Rheumatology

Volumn 19, Issue 3, 2009, Pages 348-350

  Nagamine, Ryuji ^a   Chen, Weijia ^a   Hara, Toshihiko ^a   Kondo, Keiichi ^a   Sugioka, Yoichi ^a  

^a Yoshizuka Hayashi Hospital   (Japan)

Author keywords

Interleukin 6; Rheumatoid arthritis; Tocilizumab; WBC count

Indexed keywords

ATLIZUMAB; C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; ERYTHROCYTE COUNT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; NEUTROPHIL COUNT; PRIORITY JOURNAL; REPRODUCIBILITY; SIDE EFFECT; THROMBOCYTE COUNT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; HUMANS; LEUKOPENIA; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6;

EID: 67349102309     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0159-z     Document Type: Article

References (5)

1. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761-9.
2. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7.
3. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis Phase I/II clinical study. J Rheumatol. 2003;30:1426-35.
4. Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: A report of two cases. Mod Rheumatol. 2009;19:64-68.
5. Suwa T, Hogg JC, English D, Van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000;279:H2954-60.